NASDAQ:APGE Apogee Therapeutics Q2 2026 Earnings Report $135.07 0.00 (0.00%) As of 09/4/2026 ProfileEarnings HistoryForecast Apogee Therapeutics EPS ResultsActual EPS-$1.14Consensus EPS -$1.07Beat/MissMissed by -$0.07One Year Ago EPSN/AApogee Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$10.00 millionBeat/MissN/AYoY Revenue GrowthN/AApogee Therapeutics Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time7:00AM ETUpcoming EarningsApogee Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Apogee Therapeutics Earnings HeadlinesApogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Global BMI IndexSeptember 3, 2026 | marketscreener.comMAbbVie Closes $10.9 Billion Acquisition of Apogee TherapeuticsSeptember 3, 2026 | finance.yahoo.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.October 2 at 1:00 AM | Banyan Hill Publishing (Ad)Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Biotechnology Select Industry IndexSeptember 3, 2026 | marketscreener.comMAbbVie Completes $10.9 Bln Acquisition Of Apogee TherapeuticsSeptember 3, 2026 | rttnews.comAbbVie seals $11B acquisition of Apogee TherapeuticsSeptember 3, 2026 | msn.comSee More Apogee Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Apogee Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your email. Email Address About Apogee TherapeuticsApogee Therapeutics (NASDAQ:APGE), Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologic medicines for inflammatory and immunologic diseases. The company’s approach emphasizes therapies designed to offer extended dosing intervals, with the goal of improving convenience and treatment options for patients with chronic conditions. Apogee’s lead program is APG777, a long-acting monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in allergic inflammation. The program is being developed for conditions including atopic dermatitis, asthma and other inflammatory diseases. The company is also advancing APG808, an extended-half-life antibody targeting the interleukin-4 receptor alpha (IL-4Rα) pathway, which is implicated in several type 2 inflammatory disorders. Apogee was established in 2022 and became a publicly traded company on the Nasdaq under the symbol APGE in 2023. The company is headquartered in San Francisco, California, and its development activities are focused on addressing unmet needs in inflammatory and immunologic diseases. Apogee is led by Chief Executive Officer Michael Henderson.View Apogee Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
